ROMEO, Maria Anele
 Distribuzione geografica
Continente #
NA - Nord America 1.028
EU - Europa 471
AS - Asia 129
SA - Sud America 8
AF - Africa 5
Totale 1.641
Nazione #
US - Stati Uniti d'America 1.017
IT - Italia 288
IN - India 47
SG - Singapore 45
IE - Irlanda 42
CN - Cina 32
SE - Svezia 27
FI - Finlandia 20
BG - Bulgaria 17
DE - Germania 14
GB - Regno Unito 11
ES - Italia 10
FR - Francia 10
UA - Ucraina 9
CA - Canada 8
CL - Cile 7
GR - Grecia 6
RO - Romania 5
CY - Cipro 3
MX - Messico 3
RU - Federazione Russa 3
ZA - Sudafrica 3
AT - Austria 2
CH - Svizzera 2
HR - Croazia 2
JP - Giappone 2
TG - Togo 2
AR - Argentina 1
IS - Islanda 1
PL - Polonia 1
PT - Portogallo 1
Totale 1.641
Città #
Fairfield 149
Rome 137
Chandler 90
Ashburn 69
Seattle 59
Houston 57
Woodbridge 57
Wilmington 51
Cambridge 50
Dublin 41
New York 38
Princeton 33
San Paolo di Civitate 31
Lawrence 26
Dearborn 22
Helsinki 19
Millbury 17
Sofia 17
Boston 15
Ann Arbor 14
Menlo Park 14
Beijing 13
San Diego 13
Singapore 12
Andover 11
Barcelona 10
Milan 10
Los Angeles 9
Toronto 8
Plano 7
Shanghai 7
Athens 5
Bremen 5
Cerveteri 5
Genoa 5
Norwalk 5
Santiago 5
Chicago 4
Sacramento 4
Altavilla Vicentina 3
Brescia 3
Edinburgh 3
Gainesville 3
Limassol 3
London 3
San Mateo 3
Trento 3
Trieste 3
Washington 3
Anguillara 2
Aprilia 2
Aubusson 2
Bern 2
Bovisio-Masciago 2
Bühl 2
Chengdu 2
Johannesburg 2
Lomé 2
Mannheim 2
Montereale Valcellina 2
Pune 2
Stockholm 2
Ueuchi 2
Vienna 2
Aigaleo 1
Aksay 1
Atlanta 1
Baotou 1
Bucharest 1
Campobasso 1
Charlotte 1
Ciampino 1
Codroipo 1
Des Moines 1
Falls Church 1
Federal 1
Frankfurt am Main 1
Gostyn 1
Grafing 1
Guangzhou 1
Hefei 1
Huzhou 1
Jacksonville 1
Jönköping 1
Keflavik 1
Kilburn 1
Kunming 1
Manchester 1
Mexico City 1
Miami Beach 1
Muizenberg 1
Nanjing 1
Nuremberg 1
Padova 1
Paese 1
Perugia 1
Phoenix 1
Pomezia 1
Prescot 1
Putignano 1
Totale 1.240
Nome #
Different outcome of targeting ERN1/IRE1 alpha and EIF2AK3/PERK in NSG mice engrafted with primary effusion lymphoma 90
Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's lymphoma 87
Stat3 phosphorylation affects p53/p21 axis and KSHV lytic cycle activation 82
Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation 78
Kaposi Sarcoma Herpes Virus (KSHV) infection inhibits macrophage formation and survival by counteracting Macrophage Colony-Stimulating Factor (M-CSF)-induced increase of Reactive Oxygen Species (ROS), c-Jun N-terminal kinase (JNK) phosphorylation and autophagy 78
HHV-6A infection dysregulates autophagy/UPR interplay increasing beta amyloid production and tau phosphorylation in astrocytoma cells as well as in primary neurons, possible molecular mechanisms linking viral infection to Alzheimer's disease 69
Bortezomib promotes KHSV and EBV lytic cycle by activating JNK and autophagy 67
Impact of HHV-6A and HHV-6B lytic infection on autophagy and endoplasmic reticulum stress 66
PGE2 released by pancreatic cancer cells undergoing ER stress transfers the stress to DCs impairing their immune function 62
Quercetin interrupts the positive feedback loop between STAT3 and IL-6, promotes autophagy, and reduces ROS, preventing EBV-driven B cell immortalization 60
HHV-6B reduces autophagy and induces ER stress in primary monocytes impairing their survival and differentiation into dendritic cells 60
KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 α-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression 60
Could autophagy dysregulation link neurotropic viruses to Alzheimer's disease? 56
Mutant p53, stabilized by its interplay with HSP90, activates a positive feed-back loop between NRF2 and p62 that induces chemio-resistance to Apigenin in pancreatic cancer cells 55
STAT3 and mutp53 Engage a Positive Feedback Loop Involving HSP90 and the Mevalonate Pathway 54
KSHV dysregulates bulk macroautophagy, mitophagy and UPR to promote endothelial to mesenchymal transition and CCL2 release, key events in viral-driven sarcomagenesis 51
VPA and TSA Interrupt the Interplay between mutp53 and HSP70, Leading to CHK1 and RAD51 Down-Regulation and Sensitizing Pancreatic Cancer Cells to AZD2461 PARP Inhibitor 50
DNA damage triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and Kaposi sarcoma herpesvirus replication 49
Viral Infection and Autophagy Dysregulation. The Case of HHV-6, EBV and KSHV 47
The cross-talk between STAT1/STAT3 and ROS up-regulates PD-L1 and promotes the release of pro-inflammatory/immune suppressive cytokines in primary monocytes infected by HHV-6B 45
PBA preferentially impairs cell survival of glioblastomas carrying mutp53 by reducing its expression level, stabilizing wtp53, downregulating the mevalonate kinase and dysregulating UPR 44
Anticancer effect of AZD2461 PARP inhibitor against colon cancer cells carrying wt or dysfunctional p53 44
p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53 42
The dysregulation of autophagy and ER stress induced by HHV-6A infection activates pro-inflammatory pathways and promotes the release of inflammatory cytokines and cathepsin S by CNS cells 41
The impairment of DDR reduces XBP1s, further increasing DNA damage, and triggers autophagy via PERK/eIF2alpha in MM and IRE1alpha/JNK1/2 in PEL cells 41
Targeting c-Myc Unbalances UPR towards Cell Death and Impairs DDR in Lymphoma and Multiple Myeloma Cells 40
Ire1 alpha/xbp1 axis sustains primary effusion lymphoma cell survival by promoting cytokine release and stat3 activation 40
Role of upr sensor activation in cell death–survival decision of colon cancer cells stressed by dpe treatment 38
p62/SQSTM1 promotes mitophagy and activates the NRF2-mediated antioxidant and anti-inflammatory response restraining EBV-driven B lymphocyte proliferation 37
New insights into curcumin-and resveratrol-mediated anti-cancer effects 31
Lovastatin reduces PEL cell survival by phosphorylating ERK1/2 that blocks the autophagic flux and engages a cross-talk with p53 to activate p21 27
Concomitant Inhibition of IRE1α/XBP1 Axis of UPR and PARP. A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas 24
ATF6 prevents DNA damage and cell death in colon cancer cells undergoing ER stress 19
NFE2L2 and STAT3 converge on common targets to promote survival of primary lymphoma cells 16
c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway 14
The inhibition of IRE1alpha/XBP1 axis prevents EBV-driven lymphomagenesis in NSG mice 11
NRF2 and STAT3: friends or foes in carcinogenesis? 7
HHV-6A Infection of Papillary Thyroid Cancer Cells Induces Several Effects Related to Cancer Progression 6
mTORC1/ERK1/2 Interplay Regulates Protein Synthesis and Survival in Acute Myeloid Leukemia Cell Lines 5
JQ-1/bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of prosurvival mechanisms 3
Acetylation increases expression, interaction with TRAPPC4 and surface localization of PD-L1 2
Totale 1.798
Categoria #
all - tutte 5.998
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.998


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201935 0 0 0 0 0 0 0 0 0 0 13 22
2019/2020253 17 5 15 7 26 33 39 29 44 14 10 14
2020/2021269 24 20 13 11 6 0 9 19 18 47 32 70
2021/2022437 2 16 23 17 38 17 6 43 24 23 143 85
2022/2023418 70 72 7 31 81 30 4 32 33 2 40 16
2023/2024359 29 29 14 26 49 65 23 31 12 44 37 0
Totale 1.798